Mark Currie, Ph.D.
Senior Vice President of Research and Development, Ironwood Pharmaceutical Inc.
Chief Scientific Officer, Ironwood Pharmaceutical Inc.
Mark Currie currently serves as Ironwood Pharmaceutical Inc’s. Senior Vice President of Research and Development and Chief Scientific Officer. He has led the company’s R&D efforts since joining in 2002. Dr. Currie has over 30 issued US patents and is the primary inventor of linaclotide which is a 14 amino acid peptide that activates guanylate cyclase-c and is first in class. The drug, which reduces abdominal pain and addresses large unmet need, has had 4 highly successful phase 3 trials in chronic constipation and irritable bowel syndrome (IBS). Linaclotide has the potential to markedly improve the treatment of IBS patients suffering from chronic abdominal pain. Prior to joining Ironwood, he directed cardiovascular and central nervous system disease research as Vice President of Discovery Research at Sepracor Inc. While there he led discovery and supported development of Xopenex and Lunesta.
Previously, Dr. Currie initiated, built, and led discovery pharmacology and served as Director of Arthritis and Inflammation at Monsanto Company. Mark’s successful leadership and management of these efforts led to significant breakthroughs in the treatment of human diseases including, arthritis, acute and chronic pain, asthma, and insomnia with contributions to multiple medicines (e.g., Celebrex, Xopenex, and Lunesta). Additionally, he has made substantial contributions to the scientific literature with over 100 publications that include the discoveries of three hormones that regulate blood pressure and fluid homeostasis (atrial natriuretic peptide, guanylin, and uroguanylin) and he directed the group that discovered and developed Celebrex, Bextra, and Dynastat. Dr. Currie earned a B.S. in biology from the University of South Alabama and holds a Ph.D. in cell biology from the Bowman-Gray School of Medicine of Wake Forest